HHS Boosts AI Funding for Childhood Cancer Research
A New Dawn in the Fight Against Childhood Cancer: AI and Doubled Funding Offer Hope
WASHINGTON D.C. – Tuesday, September 30, 2025 – For every parent, the words “childhood cancer” strike a primal fear. It remains the leading cause of disease-related death for children in the United States, a devastating reality compounded by a more than 40% increase in incidence as 1975. But today,a powerful new alliance of human ingenuity and artificial intelligence has been forged,promising to rewrite the future for our youngest patients.
In a landmark move at the White House, President Trump signed an executive order titled Unlocking Cures for Pediatric Cancer with Artificial Intelligence, signaling a profound shift in the nation’s approach to this relentless disease. This order is immediately backed by a doubling of funding for the National Institutes of Health’s (NIH) Childhood Cancer Data Initiative (CCDI), propelling its budget from $50 million to $100 million. The U.S. Department of Health and Human Services (HHS) announced this surge, designed to accelerate the development of improved diagnostics, treatments, and prevention strategies.
The CCDI, established by President Trump in 2019, has been a cornerstone in collecting, generating, and analyzing crucial childhood cancer data. Now, with this enhanced federal investment, the initiative will also bring in private-sector partners to apply advanced artificial intelligence to speed up cures for pediatric cancer.
“For too long,families have fought childhood cancer while our systems lagged behind,” said HHS Secretary robert F. Kennedy, Jr.,who joined President Trump alongside NIH Director Jay Bhattacharya and National Cancer Institute (NCI) Director Anthony Letai at the White House. “President Trump is changing that. We will harness American innovation in artificial intelligence to find cures for pediatric cancer.”
The commitment to leveraging cutting-edge technology was echoed by NIH Director Jay Bhattacharya, M.D., Ph.D. “We are dedicated to using every innovative method and technology at our disposal in our fight against childhood cancer,” he stated. ”By doubling down on this mission with AI, we are ensuring that state-of-the-art science is being leveraged to provide answers about thes diseases that would or else be out of reach.”
This declaration holds particular significance for NCI Director Anthony letai, M.D., Ph.D., who was sworn into his role just yesterday, September 29, 2025. “Our efforts have helped us learn from every child and better understand childhood cancer, reduce its risk, develop better treatments, and improve survivorship for children, teens and young adults with cancer,” Letai said. “I cannot think of a better way to begin my tenure at NCI than to redouble our efforts to support our youngest patients and their families facing rare leukemias and other cancers. We will not stop until childhood cancer is a thing of the past.”
The heart of this new strategy lies in data. HHS will utilize artificial intelligence to maximize the potential of electronic health record and claims data, informing research and clinical trial design with unprecedented precision.Crucially, the initiative emphasizes a people-first approach to privacy: parents will remain in control of their child’s health details as this vital data is used to benefit patients and researchers.
This directive aligns with the President’s Make American Healthy Again (MAHA) Commission’s Strategy report,which explicitly directs HHS to “focus on research that harnesses AI to uncover causes,identify risks early,and take action in childhood and young adulthood to prevent cancer.”
The impact of such data-driven research is already evident in the scientific community. Consider the meticulous work of Anthony B. Eason from Dirk Dittmer’s lab at the University of North Carolina Lineberger comprehensive Cancer Center. Their imaging and histochemistry, for example, depict HHV-8 Latency-Associated Nuclear Antigen (LANA) expression in an immunohistochemical (IHC) stain of a Kaposi sarcoma (KS) biopsy. This particular biopsy, obtained from the lymph node of a pediatric patient in Malawi, reveals LANA identified by dark red staining of the nuclei, with LANA-negative nuclei counterstained blue with hematoxylin. The KS cells display a classic spindle cell phenotype, with disruption of the lymph node architecture, all captured at 200X magnification. Such detailed examination of IHC markers from patient samples allows researchers to correlate findings with clinical data and, ultimately, improve patient outcomes. This is the kind of granular, patient-centric data that the expanded CCDI, supercharged by AI, aims to amplify exponentially.
The National Cancer Institute (NCI) leads the National Cancer Programme and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of people with cancer. NCI supports a wide range of cancer research and training thru grants and contracts, and its intramural research program conducts innovative, transdisciplinary basic, translational, clinical, and epidemiological research on the causes of cancer, avenues for prevention, risk prediction, early detection, and treatment, including research at the NIH Clinical Center-the world’s largest research hospital. More information about cancer can be found at https://www.cancer.gov.
Today’s announcement marks a pivotal moment, transforming the fight against childhood cancer from a battle fought in isolation to a coordinated, data-powered offensive. For the children and families facing this diagnosis, it offers not just hope, but a tangible promise of a future where childhood cancer is truly a thing of the past.